Mithra

Mithra Pharmaceuticals SA is a Belgian biotech company founded in 1999 with a mission to revolutionize Women’s Health through innovative products in the fields of contraception, menopause, and hormone-dependent cancers. The company is dedicated to offering women new choices by developing products that prioritize efficacy, safety, and convenience, tailored to meet women’s health needs across their lifespan.

Mithra’s innovative approach includes exploring the potential of the unique native estrogen estetrol in various applications beyond women's health. The company made a significant breakthrough with the launch of its first estetrol-based product, the contraceptive pill Estelle®, in 2021. The company is now focusing on its upcoming product, Donesta®, which is positioned as the next generation of hormone therapy.

In addition to product development, Mithra operates as a Contract Development and Manufacturing Organization (CDMO), providing a complete spectrum of research, development, and specialist manufacturing services at its technological platform. With a strong global presence in over 100 countries, Mithra Pharmaceuticals SA, headquartered in Liège, Belgium, has an approximate headcount of 300 staff members.

Despite a successful track record, Mithra continues to attract investor interest, securing a notable $13.50 million post-IPO debt investment on 05 February 2024, with the backing of Highbridge Capital Management. The company's dedication to innovation and focus on women's health makes it a compelling player in the Biotechnology, Health Care, and Pharmaceutical industries.

For more information, visit www.mithra.com.